Maybe, just maybe, 2022 Part B premium may come down

[Telly]

WASHINGTON — Department of Health and Human Services Secretary Xavier Becerra on Monday took the highly unusual step of ordering Medicare to reconsider a historic hike in premiums after Biogen slashed the price for its controversial Alzheimer’s drug in half.
“With the 50% price drop of Aduhelm on January 1, there is a compelling basis for CMS to reexamine the previous recommendation,” Becerra said in a written statement.

Biogen cut the price of Aduhelm from $56,000 per year to $28,200 in December after dismal uptake of the drug. A number of prominent academic medical centers have refused to administer the drug.

I suggest folks on Medicare read the whole short article:

https://www.statnews.com/2022/01/10/becerra-medicare-aduhelm-reconsider-price/